NCT01067989

Low-Dose/Metronomic(LDM)Chemotherapy for Metastatic Breast Cancer

Antiangiogenic Treatment Strategy With Metronomic Chemotherapy Regimen Combined With a Cox-2 Inhibitor and a Bisphosphonate for Patients With Metastatic Breast Cancer

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 22 (actual)
• Sponsor: HaEmek Medical Center, Israel · Academic / Other
• Sex: Female
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Low-dose metronomic(LDM)chemotherapy as well as anti-inflammatory agents and bisphosphonates have shown anti-angiogenic properties on tumor vasculature. This study is meant to test the therapeutic potential of an anti-angiogenic treatment strategy by combining all these agents for metastatic breast cancer patients.

Conditions

• Chemotherapy
• Breast Cancer, Metastatic

Interventions

Type	Name	Description
DRUG	Cyclophosphamide, Capecitabine, Methotrexate, Celecoxib, Pamidronate (or Zoledronate)	1. Cyclophosphamide Tab. 50mg, 1x1/day, continuously. 2. Capecitabine Tab. 500mg, 1+2/day, continuously. 3. Methotrexate Tab. 2.5mg, 1x2/day, 2 days every week. 4. Celecoxib Tab. 200mg, 1x2/day, continuously. 5. Pamidronate I.V. 90mg, every 4 weeks; or Zoledronate I.V. 4mg, every 4 weeks)

Timeline

• Start date: 2010-03-01
• Primary completion: 2014-04-01
• Completion: 2014-04-01
• First posted: 2010-02-12
• Last updated: 2015-07-08

Locations

1 site across 1 country: Israel